Dr. Vipul Patel, medical director of the Global Robotics Institute at AdventHealth Celebration, performed a robotic prostatectomy on a 66-year-old cancer patient 35 miles away at an AdventHealth facility in Minneola, Florida. The patient, identified only as Mark, was recovering well after the Sunday procedure. An onsite surgeon, Marcio Moschovas, stood by throughout — a failsafe requirement given the technology's infancy. This was not Patel's first telesurgery. He had already completed 10 investigational procedures between Orlando and Luanda, Angola — a distance of roughly 5,000 miles. Sunday's operation was notable as the first documented telesurgery between two US hospitals, expanding the study from transcontinental proof-of-concept to a domestic clinical context that regulators and insurers will eventually have to reckon with. The procedure was conducted under an FDA investigational device exemption, which permits study but does not constitute approval or clearance. AdventHealth was careful to note that the single surgery does not establish the technology's general clinical performance. This is research, not rollout. The distinction matters because the hype-to-deployment pipeline in surgical robotics has historically outrun the evidence base. The generative promise is real but distant. Roughly 60 million Americans live in areas designated as health professional shortage zones. Complex surgical specialties — urologic oncology, cardiac surgery, neurosurgery — are concentrated in urban academic centers. If telesurgery matures, it could decouple specialist access from geography. That is a structural change in how healthcare capacity is distributed, not just a faster ambulance. The friction costs are substantial. Telesurgery adds failure modes that open surgery does not have: network latency, connection drops, equipment malfunction, and cybersecurity vulnerabilities. The London-to-Gibraltar telesurgery earlier this year demonstrated a latency of just 0.06 seconds, but that was a controlled environment. Real-world US hospital networks vary wildly in reliability. An on-site surgical team must be present for every procedure, which partially undermines the cost savings the technology promises. The standard risks of robotic prostatectomy — bleeding, infection, incontinence, erectile dysfunction, conversion to open surgery — remain unchanged. Telesurgery layers network and cyber risk on top. The question is whether the access benefit for underserved populations eventually outweighs the additional risk profile, and that answer requires large-sample clinical data that does not yet exist. The 20-year question is whether telesurgery follows the trajectory of telemedicine broadly — initial skepticism, pandemic-era acceleration, gradual regulatory accommodation — or whether the physical stakes of remote surgery create a permanently higher bar. The technology works. The unresolved problems are institutional: liability frameworks, reimbursement models, bandwidth guarantees, and the political economy of who pays for the on-site backup team in a rural hospital that couldn't afford a specialist in the first place.
